University of Minnesota research team discovers new therapy potential for Duchenne Muscular Dystrophy

Researchers in the University of Minnesota College of Science and Engineering and Medical School have identified a new approach that could change the way Duchenne Muscular Dystrophy (DMD) is treated. Several CEMS researchers — Professors Frank Bates, Benjamin Hackel, and Tim Lodge, along with ChemE PhD candidate Joseph Hassler — are co-authors on this cross-disciplinary study.

The findings were recently published in PNAS, one of the world's most-cited and comprehensive multidisciplinary scientific journals.

DMD is a genetic disease that causes muscles to weaken and deteriorate over time, often leading to severe disability and early death. Globally, about 20,000 children are diagnosed with DMD each year. Currently, there is no cure.

The researchers developed a new type of therapy using a “bottlebrush polymer,” a highly branched synthetic molecule designed to protect muscle cell membranes from damage. This approach directly targets fragile muscle membranes that break down under stress, which is the root problem in DMD.

Learn more about this exciting development at the College of Science and Engineering's website.